2026-06-14T06:44:09Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/109942024-11-29T19:47:16Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597

00925njm 22002777a 4500 dc Font, Albert author Domènech, Montserrat author Benítez, Raquel author Rava, Marta author Marqués, Miriam author Ramírez, Jose L author Pineda, Silvia author Domínguez-Rodríguez, Sara author Gago, José L author Badal, Josep author Carrato, Cristina author López, Héctor author Quer, Ariadna author Castellano, Daniel author Malats, Nuria author Real Arribas, Francisco author 2020-07-03 Platinum-based neoadjuvant chemotherapy (NAC) increases the survival of patients with organ-confined urothelial bladder cancer (UBC). In retrospective studies, patients with basal/squamous (BASQ)-like tumors present with more advanced disease and have worse prognosis. Transcriptomics-defined tumor subtypes are associated with response to NAC. To investigate whether immunohistochemical (IHC) subtyping predicts NAC response. Patients with muscle-invasive UBC having received platinum-based NAC were identified. Tissue microarrays were used to type tumors for KRT5/6, KRT14, GATA3, and FOXA1. progression-free survival and disease-specific survival; univariable and multivariate Cox regression models were applied. We found a very high concordance between mRNA and protein expression. Using IHC-based hierarchical clustering, we classified 126 tumors in three subgroups: BASQ-like (FOXA1/GATA3 low; KRT5/6/14 high), Luminal-like (FOXA1/GATA3 high; KRT5/6/14 low), and mixed-cluster (FOXA1/GATA3 high; KRT5/6 high; KRT14 low). Applying multivariable analyses, patients with BASQ-like tumors were more likely to achieve a pathological response to NAC (OR 3.96; p = 0.017). The clinical benefit appeared reflected in the lack of significant survival differences between patients with BASQ-like and luminal tumors. Patients with BASQ-like tumors-identified through simple and robust IHC-have a higher likelihood of undergoing a pathological complete response to NAC. Prospective validation is required. Cancers (Basel). 2020;12(7):1784 10.3390/cancers12071784 2072-6694 Cancers 32635360 http://hdl.handle.net/20.500.12105/10994 BLADDER-CANCER Neoadjuvant chemotherapy Mmolecular taxonomy Immunohistochemistry Squamous-like tumors Basal Immunohistochemistry-Based Taxonomical Classification of Bladder Cancer Predicts Response to Neoadjuvant Chemotherapy.